Premium
Hormonelle Antiandrogene in der Aknetherapie
Author(s) -
Zouboulis Christos C.,
Rabe Thomas
Publication year - 2010
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - German
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/j.1610-0387.2009.07171.x
Subject(s) - antiandrogen , cyproterone acetate , flutamide , medicine , endocrinology , dienogest , spironolactone , polycystic ovary , antiandrogens , androgen , acne , desogestrel , hyperandrogenism , hormone , androgen receptor , population , aldosterone , prostate cancer , cancer , insulin , endometriosis , dermatology , insulin resistance , environmental health , family planning , research methodology
An enhanced sebaceous gland activity with production of proinflammtory sebaceous lipids belongs to the major pathogenetic factors of acne. Hormonal antiandrogen treatment targets the androgen-metabolizing cells of the pilosebaceous unit, i. e. follicular kertinocytes and sebocytes, and leads to sebostasis, with a reduction of the sebum secretion rate of 12.5 to 65 %. Concerning their mechanism of action, hormonal antiandrogens are classified in androgen receptor blockers, inhibitors of circulating androgens by affecting the ovarial function (oral contraceptives), inhibitors of circulating androgens by affecting the pituitary (gonadotrophin-releasing hormone agonists and dopamin agonists in hyperprolactinemia), inhibitors of the adrenal function, and inhibitors of peripheral androgen metabolism (5-reductase inhibitors, inhibitors of other enzymes).